Fezolinetant
Phase 3 study shows efficacy of fezolinetant in treating menopausal vasomotor symptoms
SAN DIEGO — Compared with placebo, fezolinetant was efficacious in the treatment of menopause-related vasomotor symptoms with no safety concerns, according to phase 3 data presented at the ACOG Annual Clinical & Scientific Meeting.
20 years of data lead to changes in perceptions, usage of menopausal HT
During the past 2 decades, Endocrine Today has reported on the latest developments in hormone therapy for symptoms associated with menopause. For its 20th year, the publication is taking a look back.
Phase 3 clinical trial shows long-term safety of menopausal vasomotor symptom therapy
Results from the phase 3 SKYLIGHT 4 clinical trial supported the long-term safety of a nonhormonal therapy for vasomotor symptoms of menopause, according to a press release from Astellas Pharma Inc.
Nonhormonal therapy reduces moderate to severe menopausal hot flashes
An investigational nonhormonal therapy for moderate to severe hot flashes significantly reduced symptom frequency at 12 weeks compared with placebo, with improvements observed as early as 1 week after treatment, data from SKYLIGHT 2 show.
Top-line results: Nonhormonal drug reduces menopausal hot flash severity
Two phase 3 trials assessing an investigational oral, nonhormonal compound for the treatment of moderate to severe hot flashes in menopausal women met their coprimary endpoints, according to top-line data from the SKYLIGHT studies.